Image source: Getty Images.
There hasn’t been much good news for Celldex Therapeutics (NASDAQ: CLDX) in 2016. Failure of Rintega in a late-stage study resulted in a loss of roughly 80% of the biotech’s market cap. Celldex announced its third-quarter results after the market closed on Monday. Were there any hints of better days to come?